According to Future Market Insights, the Castration-Resistant Prostate Cancer (CRPC) Treatment Market Demand is predicted to develop at a 9.5% CAGR from 2023 to 2033. The global market for Castration-Resistant Prostate Cancer (CRPC) Treatment is estimated to reach a value of US$ 28 billion by 2033. The increasing frequency of CRPC, together with increased knowledge and diagnosis of the disease, is one of the primary drivers of market expansion. Furthermore, the industry is being driven by the emergence of innovative medications with higher efficacy and fewer adverse effects than established therapy.
Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that has developed resistance to standard hormone therapy (also known as androgen deprivation therapy or ADT). In CRPC, the cancer grows despite reduced testosterone levels in the body, which is often the result of surgical or medicinal castration.
Unveil the Future Opportunities in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market – Get Sample Report Today! https://www.futuremarketinsights.com/reports/sample/rep-gb-16739
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Drivers:
The rising incidence of prostate cancer, one of the most common malignancies among men, is pushing the need for efficient CRPC treatments. The introduction of novel therapy alternatives, such as targeted treatments, immunotherapies, and radiopharmaceuticals, has broadened the treatment possibilities for CRPC.
The ageing population is more vulnerable to prostate cancer and CRPC, and this demographic trend is increasing the demand for better therapies. The availability of diagnostic tools such as imaging technologies, genomic testing, and liquid biopsies has enhanced CRPC detection and monitoring, adding to the demand for effective therapies.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Restraints:
Many of the existing CRPC therapy options are costly, making them unavailable to individuals who cannot afford them or are not covered by health insurance. Many CRPC treatments, like as chemotherapy and immunotherapy, have severe side effects that negatively influence a patient’s quality of life. This might make it difficult for patients to accept their treatments and stick to their treatment programmes.
While there are various therapy options for CRPC, not all of them work for every patient. Certain treatments may not work for some patients, limiting the efficacy of the available options. Some patients may acquire resistance to existing medicines, making it difficult to control their disease and extend their survival.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Report available at a discounted price: https://www.futuremarketinsights.com/request-discount/rep-gb-16739
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Regional Insights:
Because of the high frequency of prostate cancer in the region and the availability of modern healthcare infrastructure, the North American market for Castration-Resistant Prostate Cancer (CRPC) Treatment is one of the largest in the world.
Chemotherapy and hormone therapy have long been the cornerstones of CRPC treatment in North America, although more targeted medicines such as abiraterone, enzalutamide, apalutamide, and radium-223 have also been approved. Immunotherapy, such as the use of immune checkpoint inhibitors, is also being studied as a treatment for CRPC. As a result, North America is predicted to have 46% of the market for Castration-Resistant Prostate Cancer (CRPC) Treatment in 2023.
The increasing frequency of the disease in the region, as well as increased awareness and diagnosis of the ailment, are driving the Europe CRPC therapy market. Furthermore, the industry is being driven by the emergence of innovative medications with higher efficacy and fewer adverse effects than established therapy.
Castration-Resistant Prostate Cancer (CRPC) Treatment Market Competitive Landscape:
Key players in the Castration-Resistant Prostate Cancer (CRPC) Treatment market are:
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc
- Dendreon Corporation
- Sanofi, a key player in CRPC treatment market is involved in the development of other drugs for the treatment of cancer more broadly, including immunotherapies and targeted therapies.
- in 2019, Abbott announced the launch of a new clinical trial to investigate the use of their drug, ABT-199, in combination with enzalutamide (Xtandi) for the treatment of metastatic CRPC. ABT-199 is a targeted therapy that works by inhibiting a protein called BCL-2, which is overexpressed in many cancer cells.
Request Customized Analysis to Stay Ahead in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market: https://www.futuremarketinsights.com/customization-available/rep-gb-16739
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Castration-Resistant Prostate Cancer (CRPC) Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey:
Therapy Type:
- Hormonal therapy
- Chemotherapy
- Immunotherapy
- Radiotherapy
Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
Drug Delivery Method:
- Oral Route
- Injectable Route
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs